Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Review on the Myopia Pandemic: Epidemiology, Risk Factors, and Prevention.

Literature DB >> 33840860

Review on the Myopia Pandemic: Epidemiology, Risk Factors, and Prevention.

James R Landreneau¹, Nathan P Hesemann¹, Maggie A Cardonell¹.

Abstract

Nearsightedness, or myopia, is becoming more prevalent worldwide. The eye experiences dynamic growth throughout adolescence, but the etiopathogenesis of myopia progression is not fully understood. Myopia is associated with several pathologic eye conditions, leading to irreversible vision loss. Treatment for preventing myopia progression is reliant on effective screening and initiating treatment early in life. This article will review risk factors for myopia progression and discuss treatment strategies that are most effective in halting its spread. Copyright 2021 by the Missouri State Medical Association.

Entities: Chemical

Mesh：

Year: 2021 PMID： 33840860 PMCID： PMC8029638

Source DB: PubMed Journal: Mo Med ISSN： 0026-6620

Keyword Cloud
References

48 in total

1. Role of genetic factors in the etiology of juvenile-onset myopia based on a longitudinal study of refractive error.

Authors: R Pacella; J McLellan; K Grice; E A Del Bono; J L Wiggs; J E Gwiazda
Journal: Optom Vis Sci Date: 1999-06 Impact factor: 1.973

Review 2. Vision Screening in Children Aged 6 Months to 5 Years: Evidence Report and Systematic Review for the US Preventive Services Task Force.

Authors: Daniel E Jonas; Halle R Amick; Ina F Wallace; Cynthia Feltner; Emily B Vander Schaaf; Callie L Brown; Claire Baker
Journal: JAMA Date: 2017-09-05 Impact factor: 56.272

3. A 3-year Randomized Clinical Trial of MiSight Lenses for Myopia Control.

Authors: Paul Chamberlain; Sofia C Peixoto-de-Matos; Nicola S Logan; Cheryl Ngo; Deborah Jones; Graeme Young
Journal: Optom Vis Sci Date: 2019-08 Impact factor: 1.973

4. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2).

Authors: Audrey Chia; Wei-Han Chua; Yin-Bun Cheung; Wan-Ling Wong; Anushia Lingham; Allan Fong; Donald Tan
Journal: Ophthalmology Date: 2011-10-02 Impact factor: 12.079

5. Use of Orthokeratology for the Prevention of Myopic Progression in Children: A Report by the American Academy of Ophthalmology.

Authors: Deborah K VanderVeen; Raymond T Kraker; Stacy L Pineles; Amy K Hutchinson; Lorri B Wilson; Jennifer A Galvin; Scott R Lambert
Journal: Ophthalmology Date: 2018-11-23 Impact factor: 12.079

Review on the Myopia Pandemic: Epidemiology, Risk Factors, and Prevention.

1. Role of genetic factors in the etiology of juvenile-onset myopia based on a longitudinal study of refractive error.

Review 2. Vision Screening in Children Aged 6 Months to 5 Years: Evidence Report and Systematic Review for the US Preventive Services Task Force.

3. A 3-year Randomized Clinical Trial of MiSight Lenses for Myopia Control.

4. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2).

5. Use of Orthokeratology for the Prevention of Myopic Progression in Children: A Report by the American Academy of Ophthalmology.

Review 6. Neural control of eye growth and experimental myopia in primates.

7. Myopia stabilization and associated factors among participants in the Correction of Myopia Evaluation Trial (COMET).

8. Retardation of myopia in Orthokeratology (ROMIO) study: a 2-year randomized clinical trial.

9. Asymmetrical increase in axial length in the two eyes of a monocular orthokeratology patient.

10. Patterns of posterior ocular complications in myopic eyes of Indian population.